Scarica l'app Stockscreener
1.49
0.00%
0.00
Dopo l'orario di chiusura:
1.50
0.01
+0.67%
Precedente Chiudi:
$1.49
Aprire:
$1.5
Volume 24 ore:
3.09M
Relative Volume:
1.14
Capitalizzazione di mercato:
$334.85M
Reddito:
$95,000
Utile/perdita netta:
$-327.27M
Rapporto P/E:
-0.7028
EPS:
-2.12
Flusso di cassa netto:
$-239.25M
1 W Prestazione:
+8.76%
1M Prestazione:
+2.76%
6M Prestazione:
+24.17%
1 anno Prestazione:
-36.60%
Intervallo 1D:
$1.455
$1.5399
Intervallo di 1 settimana:
$1.31
$1.54
Portata 52W:
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Nome
Allogene Therapeutics Inc
Settore
Industria
Telefono
(650) 457-2700
Indirizzo
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Confronta ALLO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.49 | 334.85M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-05-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | Ripresa | Oppenheimer | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-01-05 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-01-05 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | Iniziato | Citigroup | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-06 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-08-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-03 | Iniziato | Robert W. Baird | Neutral |
| 2022-02-28 | Reiterato | B. Riley Securities | Buy |
| 2021-10-20 | Iniziato | Cowen | Outperform |
| 2021-10-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-10-08 | Downgrade | Stifel | Buy → Hold |
| 2021-09-23 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | Ripresa | Jefferies | Buy |
| 2021-05-20 | Aggiornamento | Truist | Hold → Buy |
| 2021-05-14 | Iniziato | B. Riley Securities | Buy |
| 2021-01-26 | Aggiornamento | Stifel | Hold → Buy |
| 2020-12-10 | Ripresa | H.C. Wainwright | Buy |
| 2020-11-24 | Iniziato | BofA Securities | Buy |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-06-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-19 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2020-05-15 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-05-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-14 | Downgrade | SunTrust | Buy → Hold |
| 2020-04-13 | Iniziato | SunTrust | Buy |
| 2020-03-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-24 | Iniziato | Berenberg | Hold |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-11-04 | Iniziato | Canaccord Genuity | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-06-05 | Iniziato | ROTH Capital | Neutral |
| 2019-05-31 | Iniziato | Guggenheim | Neutral |
| 2019-05-23 | Iniziato | Stifel | Hold |
| 2019-03-29 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie
Can Allogene Therapeutics Inc. stock outperform in 2025 bull marketOptions Play & Long-Term Growth Portfolio Plans - ulpravda.ru
Will Allogene Therapeutics Inc. stock reach Wall Street targetsJuly 2025 Decliners & Fast Gain Stock Trading Tips - ulpravda.ru
How Allogene Therapeutics Inc. stock reacts to bond yieldsEarnings Growth Report & Consistent Profit Trade Alerts - ulpravda.ru
Allogene outlines 2026 clinical milestones for off-the-shelf CAR T - Investing.com India
Allogene Therapeutics interim futility analysis of MRD clearance from phase 2 Alpha3 trial planned for early Q2 2026 - MarketScreener
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T - Yahoo Finance
Is Allogene Therapeutics Inc. stock a buy in volatile marketsQuarterly Earnings Review & Access Risk Ratings for Every Stock - ulpravda.ru
UBS Initiates Coverage of Allogene Therapeutics (ALLO) with Buy Recommendation - Nasdaq
UBS Initiates Coverage on Allogene Therapeutics (ALLO) with 'Buy' Rating | ALLO Stock News - GuruFocus
UBS initiates coverage on Allogene stock with Buy rating, $8 price target By Investing.com - Investing.com South Africa
UBS initiates coverage on Allogene stock with Buy rating, $8 price target - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Allogene Therapeutics (ALLO) - The Globe and Mail
Is Allogene Therapeutics Inc. stock attractive for growth ETFsQuarterly Growth Report & Real-Time Volume Spike Alerts - Улправда
Why Allogene Therapeutics Inc. stock is favored by pension fundsTreasury Yields & Daily Entry Point Trade Alerts - Улправда
Why Allogene Therapeutics Inc. stock is seen as undervaluedMarket Activity Recap & Verified Stock Trade Ideas - Улправда
Allogene Therapeutics Earnings Notes - Trefis
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Benzinga
Allogene stock rises after favorable arbitration ruling reaffirms therapy rights By Investing.com - Investing.com South Africa
Allogene Therapeutics (ALLO) Solidifies Global Rights to Cema-ce - GuruFocus
Arbitration ruling reaffirms Allogene’s control of cancer therapy By Investing.com - Investing.com Canada
Arbitration ruling reaffirms Allogene’s control of cancer therapy - Investing.com India
Allogene Therapeutics Reaffirms Control of Cemacabtagene Ansegedleucel Following Arbitration Ruling - Quiver Quantitative
Allogene stock rises after favorable arbitration ruling reaffirms therapy rights - Investing.com
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - sahmcapital.com
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis - GlobeNewswire
Allogene (NASDAQ: ALLO) arbitration clears path to global cema-cel rights deal - Stock Titan
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
December 2025 Penny Stocks Worth Watching - simplywall.st
Allogene Therapeutics advances ALPHA3 trial to battle relapse fears - Traders Union
Will Allogene Therapeutics Inc. stock benefit from green energy trendsForecast Cut & Stock Market Timing Techniques - Newser
Allogene Therapeutics showcases ALPHA3 study at ASH25 - Traders Union
Allogene Therapeutics CEO unveils pipeline at Piper Sandler - Traders Union
Allogene Therapeutics Up 19%, But Some Insiders Miss Out - 富途牛牛
Allogene Therapeutics (NASDAQ:ALLO) Upgraded at Wall Street Zen - MarketBeat
Could a New Alternative to a Bespoke Treatment Change the Future of Cancer Care? - Katie Couric Media
Allogene upgraded at Citizens after Q4 update - MSN
Allogene Therapeutics redefines CAR T-cell therapy with allogeneic products - Traders Union
FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases - MSN
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN
Can SBC Exports Limited Deliver Through Market Peaks and TroughsResistance Zone Identification & Build Winning Portfolio - earlytimes.in
Allogene Therapeutics reports Q3 EPS (19c), consensus (23c) - MSN
Allogene Therapeutics unveils ALLO-329 to combat autoimmune diseases - Traders Union
CAR-T in NHL Treatment Market Size is estimated to grow by 2034, - openPR.com
Analyzing Allogene Therapeutics Inc. with multi timeframe chartsWeekly Stock Report & Fast Moving Trade Plans - newser.com
Detecting support and resistance levels for Allogene Therapeutics Inc.Market Movement Recap & Step-by-Step Trade Execution Guides - newser.com
[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity - Stock Titan
Why Allogene Therapeutics Inc. stock remains on watchlistsPortfolio Return Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Allogene Therapeutics Inc Azioni (ALLO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):